| Clinical
Trial: |
S0000–
SELECT – Selenium and Vitamin E Cancer Prevention |
| Governing Group: |
Southwest Oncology
Group |
| Title: |
“Selenium
and Vitamin E Prostate Cancer Prevention Trial (SELECT).” |
Eligibility:
- Participants must be male, age 55 or older (African American
men must be age 50 or older).
- Digital Rectal Exam (DRE) not suspicious for prostate cancer
and PSA less than or equal to 4.0 ng/ml, both within 180 days
prior to randomization.
- No prior diagnosis of prostate cancer or high grade PIN.
- Must not be currently taking any vitamin E or any selenium.
- Must not be taking any anticoagulation therapy except low dose
aspirin.
- Systolic blood pressure less than 160, diastolic less than
90.
- No other current clinical trial participation.
|
| Clinical
Trial: |
S9917
– Selenium – Based Prostate Cancer Prevention |
| Governing Group: |
Southwest Oncology
Group |
| Title: |
“L-Selenium-Based
Chemoprevention of Prostate Cancer Among Men with High Grade Prostatic
Intraepithelial Neoplasia.” |
Eligibility:
- Patients must be age 40 or older.
- Patients must have had a digital rectal exam (DRE) and biopsy
of the prostate with suggested TRUS guidance (required if fewer
than six cores obtained) that documents High Grade Prostatic Intrepithelial
Neoplasia (High Grade PIN or HGPIN) with no evidence of cancer.
- The biopsy must either: a.) yielded less than 10 cores within
two (2) years prior to registration, or b.) yielded 10 or more
cores within six (6) months prior to registration.
- Patients must have a PSA less than or equal to 10 ng/ml.
- Patients must have Performance Status of 0 or 1.
- Patients must agree to stop taking any dietary supplements
which contain greater than or equal to 50 mcg/day of selenium
within 30 days prior to registration.
- Patient must agree not to take supplements containing 50 mcg
or more of selenium while on study.
- Patients must not be taking finasteride or any other androgen
suppressor.
|
